Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists - Di Nisio, M; Ageno, W; Rutjes, A WS; Pap, A F; Büller, H R (Thromb Haemost, 2016)